Evidence map›Paper›PMID 38724789›Full record

ReviewAdvances in experimental medicine and biology2024

Topical Prescription Management.

Katie Lovell, Brad Ackerson, Ryan Thorpe, Matilda Nicholas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Katie LovellWake Forest University, Department of Dermatology, Winston-Salem, NC, USA.
Brad AckersonDuke University Hospital, Department of Dermatology, Durham, NC, USA.
Ryan ThorpeDuke University Hospital, Department of Dermatology, Durham, NC, USA.
Matilda NicholasDuke University Hospital, Department of Dermatology, Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With recent advances in topical therapies for atopic dermatitis (AD), steroid-sparing options like calcineurin inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase-4 (PDE-4) inhibitors are becoming mainstays in therapy, underscoring the importance of careful selection and usage of topical corticosteroids (TCSs) to minimize side effects. Alongside the necessity of emollient use, these steroid-sparing alternatives offer rapid itch relief and efficacy in improving disease severity. While TCSs still hold a prominent role in AD management, promising novel topical treatments like tapinarof and live biotherapeutics to modulate the skin microbiome are also discussed. Overall, the recent addition of novel topical therapies offers diverse options for AD management and underscores the importance of topical treatments in the management of AD.

Indexed as

Dermatitis, AtopicAdministration, CutaneousAdministration, TopicalAdrenal Cortex HormonesCalcineurin InhibitorsDermatologic AgentsHumansPhosphodiesterase 4 InhibitorsSkinAdrenal Cortex HormonesCalcineurin InhibitorsDermatologic AgentsPhosphodiesterase 4 InhibitorsAtopic dermatitisCalcineurin inhibitorsEmollientsJanus kinase (JAK) inhibitorsMaintenance therapyPhosphodiesterase-4 (PDE-4) inhibitorsSteroid-sparingTopical biotherapeuticsTopical corticosteroids (TCS)Topical medications

Identifiers

PMID38724789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.